594 related articles for article (PubMed ID: 15947080)
1. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
[TBL] [Abstract][Full Text] [Related]
2. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
Kleinschmidt-DeMasters BK; Tyler KL
N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
6. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Warnke C; Adams O; Kieseier BC
N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
[No Abstract] [Full Text] [Related]
7. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
8. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy?
Pineton de Chambrun G; Vernier-Massouille G; Viget N; Colombel JF; Yazdanpanah Y
Gut; 2008 Nov; 57(11):1633-4; author reply 1634. PubMed ID: 18941016
[No Abstract] [Full Text] [Related]
9. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major EO
N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
[No Abstract] [Full Text] [Related]
10. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
Berger JR; Koralnik IJ
N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
[No Abstract] [Full Text] [Related]
11. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
14. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Warnke C; Adams O; Hartung HP; Kieseier BC
Ann Neurol; 2011 Jan; 69(1):215-6; author reply 216. PubMed ID: 21280097
[No Abstract] [Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
16. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
Kleiter I; Schröder M; Lürding R; Schuierer G; Clifford DB; Bogdahn U; Steinbrecher A; Pöschl P
Mult Scler; 2010 Jun; 16(6):749-53. PubMed ID: 20453014
[TBL] [Abstract][Full Text] [Related]
17. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for the treatment of Crohn's disease.
Bickston SJ; Muniyappa K
Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]